|
Oprelvekin
Oprelvekin
information and resources from the National Cancer Institute
Neumega Genetics Institute, Inc Nov 25 1997
Neumega Genetics Institute, Inc Sep 18 2002
Neumega
Neumega is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia.
Genetics Institute, Inc Sep 18 2002
|
|
|
|
|
|
Oprelvekin
-->
|
